Subject(s)
Intestinal Neoplasms , Receptor, PAR-1 , Animals , Disease Progression , Humans , Male , Mice , Peptide HydrolasesABSTRACT
INTRODUCTION: Procoagulant factors promote cancer progression and metastasis. Protein C is involved in hemostasis, inflammation and signal transduction, and has a protective effect on the endothelial barrier. In mice, administration of activated protein C reduced experimental metastasis. We assessed the association between protein C and mortality in patients with three types of cancer. METHODS: The study population consisted of patients with advanced prostate, non-small cell lung or pancreatic cancer, who participated in the INPACT trial (NCT00312013). The trial evaluated the addition of nadroparin to chemotherapy in patients with advanced malignancy. Patients were divided into tertiles based on protein C at baseline. The association between protein C levels and mortality was evaluated with Cox proportional hazard models. RESULTS: We analysed 477 patients (protein C tertiles: <97, 97-121 and ≥121%). Mean age was 65±9years; 390 (82%) were male; 191 patients (40%) had prostate cancer, 161 (34%) had lung cancer, and 125 (26%) pancreatic cancer. During a median follow-up of 10.4months, 291 patients (61%) died. Median protein C level was 107% (IQR 92-129). In the lowest tertile, 75 patients per 100 patient-years died, as compared to 60 and 54 in the middle and high tertile, respectively. Lower levels of protein C were associated with increased mortality (in tertiles: HR for trend 1.18, 95%CI 1.02-1.36, adjusted for age, sex and nadroparin use; as a continuous variable: HR 1.004, 95%CI 1.00-1.008, p=0.07). CONCLUSION: Protein C seems inversely associated with mortality in patients with advanced prostate, lung and pancreatic cancer. Further research should validate protein C as a biomarker for mortality, and explore the effects of protein C on progression of cancer.
Subject(s)
Carcinoma, Non-Small-Cell Lung/blood , Lung Neoplasms/blood , Pancreatic Neoplasms/blood , Prostatic Neoplasms/blood , Protein C/analysis , Aged , Anticoagulants/therapeutic use , Biomarkers, Tumor/blood , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/mortality , Disease Progression , Female , Humans , Kaplan-Meier Estimate , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Male , Middle Aged , Nadroparin/therapeutic use , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/mortality , Proportional Hazards Models , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/mortalityABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with a 5-year mortality rate of > 50% and unknown etiology. Treatment options remain limited and, currently, only two drugs are available, i.e. nintedanib and pirfenidone. However, both of these antifibrotic agents only slow down the progression of the disease, and do not remarkably prolong the survival of IPF patients. Hence, the discovery of new therapeutic targets for IPF is crucial. Studies exploring the mechanisms that are involved in IPF have identified several possible targets for therapeutic interventions. Among these, blood coagulation factor receptors, i.e. protease-activated receptors (PARs), are key candidates, as these receptors mediate the cellular effects of coagulation factors and play central roles in influencing inflammatory and fibrotic responses. In this review, we will focus on the controversial role of the coagulation cascade in the pathogenesis of IPF. In the light of novel data, we will attempt to reconciliate the apparently conflicting data and discuss the possibility of pharmacologic targeting of PARs for the treatment of fibroproliferative diseases.
Subject(s)
Blood Coagulation/drug effects , Idiopathic Pulmonary Fibrosis/metabolism , Receptors, Proteinase-Activated/metabolism , Animals , Anticoagulants , Bleomycin/chemistry , Blood Coagulation Factors/therapeutic use , Disease Models, Animal , Disease Progression , Fibrosis/pathology , Humans , Idiopathic Pulmonary Fibrosis/mortality , Inflammation , Lactones/therapeutic use , Mice , Platelet Aggregation Inhibitors/therapeutic use , Pyridines/therapeutic use , Receptor, PAR-1/antagonists & inhibitors , Receptor, PAR-2/antagonists & inhibitors , Receptors, Proteinase-Activated/antagonists & inhibitorsABSTRACT
INTRODUCTION: In cancer, tumor progression and metastasis are promoted by prohemostatic activity. Protein C (PC) is involved in hemostasis, inflammation and signal transduction, and has a protective effect on the endothelial barrier. In mice, administration of activated PC reduced experimental metastasis. It is unclear whether PC level is associated with mortality in patients with cancer. AIM: To assess the relation between PC level and survival in patients with advanced cancer. MATERIALS AND METHODS: A multicenter, randomized, open-label study was performed in 11 countries between May 2006 and August 2008 (INPACT study, van Doormaal et al, JCO 2011). Patients (n=503) with hormone-refractory prostate cancer, non-small cell lung cancer stage IIIB and locally advanced pancreatic cancer were randomized to receive nadroparin or placebo for 6 to 46 weeks following a specific schedule. Patients were followed till death or the end of the study in May 2009. PC activity levels were measured at baseline and categorized in tertiles. The association between PC level and mortality was evaluated with Cox proportional hazard models, adjustments were made by multivariate Cox proportional hazard models. RESULTS: PC activity could be measured in 479 (95%) patients (tertiles: <97, 97-120 and >120%). Two patients with missing information on type of cancer were excluded. Mean age was 65±10 years; 87 (18%) were female; and 161 patients had lung cancer, 125 pancreatic cancer and 191 prostate cancer. During median follow-up of 10.5 months, 291 (61%) patients died. Median PC activity was 107% (IQR 92-129). There was a clear inverse relation between PC activity and mortality (p for trend=0.036). In the lowest tertile, mortality was 66%, in the middle and high tertile 61% and 56%, respectively. Compared to the highest tertile, the lowest tertile was associated with a HR on mortality of 1.36 (95% CI 1.02-1.80). Adjustment for age, gender and nadroparin use did not affect this association. The association appeared to be strongest in the patients with lung cancer, HR 0.818 (p=0.11) as compared to the patients with prostate cancer, HR 0.972 (p=0.83) and pancreatic cancer, HR 0.950 (p=0.68). CONCLUSIONS: Lower PC activity is associated with increased mortality in patients with advanced cancer. However, validation of our findings in a larger cohort is necessary. When the association of PC and mortality has been proven to be consistent, we would suggest a trial on suppletion of PC in cancer patients.
ABSTRACT
An excess of thyroid hormone leads to a prothrombotic state; however, the underlying pathophysiological mechanisms remain unknown. As evidence points towards an extensive "cross-talk" between the inflammatory and coagulation cascade, inflammation has been claimed as a possible mechanism through which different risk factors trigger venous thrombus formation. We aimed to study changes in expression of inflammation-related genes of the leukocyte RNA expression profile in healthy subjects in response to supraphysiological doses of levothyroxine. In a randomized single-blinded crossover design, 12 healthy volunteers (aged 18-40 years) received levothyroxine and no medication, both for 14 days with a wash-out period of at least 28 days between the periods. Blood was sampled at baseline and day 14 of each study period. MRNA was isolated from whole blood and used for multiplex ligation-dependent probe amplification to study the expression of inflammation-related genes. Compared to the control situation no significant changes were found in the expression of proinflammatory cytokines and mediators after the intake of levothyroxine. The results of this study show that high thyroid hormone levels do not lead to an altered inflammatory profile. This provides evidence against a major role of the inflammatory system as mediator in the effect of thyroid hormone on the coagulation system. The mechanisms by which thyroid hormone may influence coagulation proteins remain to be elucidated.
Subject(s)
Gene Expression Regulation/drug effects , Health , Inflammation/genetics , Thyroxine/pharmacology , Adult , Cross-Over Studies , Female , Humans , Inflammation/physiopathology , Male , Thyroid Function TestsABSTRACT
BACKGROUND: Protease-activated receptor 2 (PAR-2) is a G protein-coupled receptor suggested to play an important role in the proliferation and migration of tumor cells of epithelial origin. However, the role of PAR-2 in the setting of pancreatic cancer remains largely unexplored. OBJECTIVES: To understand the importance of PAR-2 in pancreatic cancer cell migration. METHODS AND RESULTS: The present study shows that PAR-2 does not affect pancreatic cancer cell proliferation but significantly induces the migration of pancreatic cancer cells in scratch assays. Interestingly, PAR-2 does not affect migration in a trans-well setting. This apparent discrepancy depends on extracellular ATP release in the scratch assays and the addition of exogenous (ATP)-induced PAR-2-dependent migration in trans-well assays, whereas a specific P2Y11 receptor antagonist prevents PAR-2-driven migration in scratch assays. In the scratch assays, inhibitors of Src, Rac, protein kinase C, mitogen-activated protein kinase kinase, p38, and epidermal growth factor (EGF) receptor blocked PAR-2-driven migration, whereas they did not affect fetal calf serum-driven wound closure. CONCLUSION: Taken together, PAR-2 activation drives pancreatic cancer cell migration via an EGF-Src-Rac-p38/mitogen-activated protein kinase kinase/EGF1/2 signaling pathway, which is facilitated by extracellular ATP. Targeting the PAR-2/ATP-driven signaling pathway may therefore limit cell migration, which could inhibit pancreatic cancer metastasis.
Subject(s)
Adenosine Triphosphate/pharmacology , Cell Movement/physiology , Pancreatic Neoplasms/pathology , Receptor, PAR-2/physiology , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation , Humans , Pancreatic Neoplasms/enzymology , Pancreatic Neoplasms/metabolismSubject(s)
CCAAT-Enhancer-Binding Protein-delta/metabolism , Escherichia coli Infections/immunology , Kidney/immunology , Urinary Tract Infections/immunology , Uropathogenic Escherichia coli/pathogenicity , Animals , Escherichia coli Infections/microbiology , Humans , Kidney/metabolism , Mice , Transcription Factors/metabolism , Urinary Tract Infections/microbiology , Uropathogenic Escherichia coli/immunologyABSTRACT
Fibrinogen and platelets play an important role in cancer cell survival in the circulation by protecting cancer cells from the immune system. Moreover, endogenous activated protein C (APC) limits cancer cell extravasation due to sphingosine-1-phosphate receptor-1 (S(1)P(1)) and VE-cadherin-dependent vascular barrier enhancement. We aimed to study the relative contribution of these two mechanisms in secondary tumor formation in vivo. We show that fibrinogen depletion limits pulmonary tumor foci formation in an experimental metastasis model in C57Bl/6 mice but not in NOD-SCID mice lacking a functional immune system. Moreover, we show that in the absence of endogenous APC, fibrinogen depletion does not prevent cancer cell dissemination and secondary tumor formation in immune-competent mice. Overall, we thus show that endogenous APC is essential for immune-mediated cancer cell elimination.
Subject(s)
Protein C/metabolism , Animals , Antigens, CD/metabolism , Blood Coagulation , Blood Platelets/metabolism , Cadherins/metabolism , Fibrinogen/metabolism , Immune System , Lung Neoplasms/metabolism , Melanoma/metabolism , Melanoma, Experimental , Mice , Mice, Inbred C57BL , Mice, SCID , Neoplasm Metastasis , Protein C/immunology , Receptors, Lysosphingolipid/metabolism , Thrombin/metabolismABSTRACT
The development of resistance against chemotherapy remains one of the major challenges in the clinical management of leukemia. There is still limited insight into the molecular mechanisms that maintain the chemotherapy-resistant phenotype, despite the obvious clinical relevance that such knowledge would have. In this study, we show that the chemotherapy-resistant phenotype of myeloid leukemia cells correlates with activation of the Hedgehog (Hh) pathway, whereas in chemosensitive cells, such activation is less pronounced. Importantly, the overexpression of Hh pathway components induces chemoprotection and inhibition of the pathway reverts chemoresistance of Lucena-1 cells, apparently by interfering with P-glycoprotein-dependent drug resistance. Our data thus identify the Hh pathway as an essential component of multidrug resistance (MDR) myeloid leukemia and suggest that targeting the Hh pathway might be an interesting therapeutic avenue for overcoming MDR resistance in myeloid leukemia.
Subject(s)
Hedgehog Proteins/physiology , Leukemia, Myeloid/drug therapy , Signal Transduction/physiology , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Cell Line, Tumor , Drug Resistance, Multiple , Drug Resistance, Neoplasm , HumansSubject(s)
Blood Proteins/genetics , Exons/genetics , Gene Duplication , Protein S Deficiency/genetics , Humans , Protein SABSTRACT
The initiator of coagulation, full-length tissue factor (flTF), in complex with factor VIIa, influences angiogenesis through PAR-2. Recently, an alternatively spliced variant of TF (asTF) was discovered, in which part of the TF extracellular domain, the transmembrane, and cytoplasmic domains are replaced by a unique C terminus. Subcutaneous tumors produced by asTF-secreting cells revealed increased angiogenesis, but it remained unclear if and how angiogenesis is regulated by asTF. Here, we show that asTF enhances angiogenesis in matrigel plugs in mice, whereas a soluble form of flTF only modestly enhances angiogenesis. asTF dose-dependently upregulates angiogenesis ex vivo independent of either PAR-2 or VIIa. Rather, asTF was found to ligate integrins, resulting in downstream signaling. asTF-alphaVbeta3 integrin interaction induces endothelial cell migration, whereas asTF-dependent formation of capillaries in vitro is dependent on alpha6beta1 integrin. Finally, asTF-dependent aortic sprouting is sensitive to beta1 and beta3 integrin blockade and a TF-antibody that disrupts asTF-integrin interaction. We conclude that asTF, unlike flTF, does not affect angiogenesis via PAR-dependent pathways but relies on integrin ligation. These findings indicate that asTF may serve as a target to prevent pathological angiogenesis.
Subject(s)
Alternative Splicing , Integrin alpha6beta1/metabolism , Integrin alphaVbeta3/metabolism , Neovascularization, Pathologic/genetics , Thromboplastin/genetics , Animals , Aorta/growth & development , Aorta/metabolism , Capillaries/growth & development , Capillaries/metabolism , Cell Movement , Endothelium, Vascular/metabolism , Factor V/metabolism , Mice , Mice, Inbred C57BL , Receptor, PAR-2/metabolismSubject(s)
Fluorobenzenes/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Pyrimidines/therapeutic use , Sulfonamides/therapeutic use , C-Reactive Protein/metabolism , Cross-Over Studies , Humans , Lipids/blood , Rosuvastatin CalciumSubject(s)
Neoplasms/drug therapy , Neoplasms/immunology , Thrombin/antagonists & inhibitors , Animals , Anticoagulants/pharmacology , Blood Coagulation , Disease Models, Animal , Disease Progression , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Melanoma, Experimental , Mice , Mice, SCID , Neoplasm Metastasis , Thrombin/immunologyABSTRACT
Hereditary protein S (PS) deficiency is an autosomal disorder caused by mutations in the PS gene (PROS1). Conventional PCR-based mutation detection identifies PROS1 point mutations in approximately 50% of the cases. To verify if gross copy number variations (CNVs) are often present in point mutation-negative hereditary PS deficiency we used multiplex ligation-dependent probe amplification (MLPA) as a detection tool in samples from individuals with a high probability of having true PS deficiency. To this end, DNA samples from nine PS deficient probands with family members (seven type I and two type III) and nine isolated probands (three type I and six type III), in whom PROS1 mutations were not found by DNA sequencing, were evaluated. An independent quantitative PCR (qPCR) was performed to confirm the findings of the MLPA assay. Family members were also tested when DNA was available. Gross abnormalities of PROS1 were found in six out of eighteen probands. In three probands complete deletion of the gene was detected. Two probands had a partial deletion involving different parts of the gene (one from exon 4 through 9 and another from exon 9 through 11). One family showed a duplication of part of PROS1. qPCR analysis was in accordance with these results. In conclusion, this study substantiates that gross gene abnormalities in PROS1 are relatively common in hereditary PS deficient patients and that MLPA is a useful tool for direct screening of CNVs in PROS1 point mutation-negative individuals.
Subject(s)
Blood Proteins/genetics , Gene Deletion , Gene Duplication , Point Mutation , Protein S Deficiency/genetics , DNA Mutational Analysis/methods , Exons , Family Health , Female , Humans , Male , Mutation , Pedigree , Polymerase Chain Reaction , Protein S/geneticsABSTRACT
BACKGROUND: Inhibition of specific coagulation pathways such as the factor VIIa-tissue factor complex has been shown to attenuate ischemia/reperfusion (I/R) injury, but the cellular mechanisms have not been explored. OBJECTIVES: To determine the cellular mechanisms involved in the working mechanism of active site inhibited factor VIIa (ASIS) in the protection against myocardial I/R injury. METHODS: We investigated the effects of a specific mouse recombinant in a mouse model of myocardial I/R injury. One hour of ischemia was followed by 2, 6 or 24 h of reperfusion. Mouse ASIS or placebo was administered before and after induction of reperfusion. RESULTS: ASIS administration reduced myocardial I/R injury by more than 40% at three reperfusion times. Multiplex ligation dependent probe amplification (MLPA) analysis showed reduced mRNA expression in the ischemic myocardium of CD14, TLR-4, interleukin-1 (IL-1) receptor-associated kinase (IRAK) and IkappaBalpha upon ASIS administration, indicative of inhibition of toll-like receptor-4 (TLR-4) and subsequent nuclear factor-kappaB (NF-kappaB) mediated cell signaling. Levels of nuclear activated NF-kappaB and proteins influenced by the NF-kappaB pathway including tissue factor (TF) and IL-6 that were increased after I/R, were attenuated upon ASIS administration. After 6 and 24 h of reperfusion, neutrophil infiltration into the area of infarction was decreased upon ASIS administration. There was, however, no evidence of an effect of ASIS on apoptosis (Tunel staining and MLPA analysis). CONCLUSIONS: We conclude that the diminished amount of myocardial I/R injury after ASIS administration is primarily due to attenuated inflammation-related lethal I/R injury, probably mediated through the NF-kappaB mechanism.
Subject(s)
Factor VIIa/pharmacology , Myocardial Reperfusion Injury/prevention & control , Animals , Factor VIIa/administration & dosage , Inflammation , Mice , Myocardial Ischemia/metabolism , Myocardial Reperfusion Injury/drug therapy , NF-kappa B/metabolism , RNA, Messenger/analysis , RNA, Messenger/drug effects , Toll-Like Receptor 4/antagonists & inhibitors , Toll-Like Receptor 4/geneticsABSTRACT
BACKGROUND: Tissue factor (TF) and factor (F) VIIa are the primary initiators of the coagulation cascade, but also promote non-hemostatic events, such as angiogenesis and tumor growth, via activation of protease activated receptor-2 (PAR2). Our previous findings indicated that the TF:FVIIa complex activates signal transducer and activator of transcription (STAT) signaling, leading to cell survival in TF-transfected baby hamster kidney (BHK) cells. METHODS: Using BHK TF, keratinocytes (HaCaT) and human umbilical vein endothelial cells (HUVEC), FVIIa-induced phosphorylation and activation of the transcription factor cyclic AMP-responsive binding protein (CREB) were tested and compared to that elicited by thrombin and FXa. In addition, the effect of these factors on cell survival and expression of apoptosis-associated proteins was monitored. RESULTS: Factor VIIa led to a TF-dependent, but TF cytoplasmic domain-independent phosphorylation and activation of CREB in BHK TF, HaCaT and HUVEC. CREB activation was sensitive to blockade of the extracellular-signal regulated kinase 1/2 pathway and PAR2. Surprisingly, FVIIa decreased cell survival in HaCaT cells but not other cell types and upregulated the pro-apoptotic proteins Bak and Puma in a CREB-dependent manner. Factor Xa, but not FIIa, induced phosphorylation of CREB, but did not have an effect on apoptosis. CONCLUSION: TF:FVIIa induces CREB phosphorylation and activation in several cell types, but TF:FVIIa induces pro-apoptotic proteins and apoptosis only in selected cell types.
Subject(s)
Apoptosis , Cyclic AMP Response Element-Binding Protein/metabolism , Factor VIIa/metabolism , Receptor, PAR-2/metabolism , Thromboplastin/metabolism , Up-Regulation , Animals , Blotting, Western , Cells, Cultured , Cricetinae , Factor Xa/metabolism , GTP-Binding Proteins/metabolism , Humans , Phosphorylation , Signal Transduction , Thrombin/metabolismABSTRACT
Barrett's esophagus (BE) is a metaplastic process in which the normal squamous epithelium of the distal esophagus is replaced by columnar lined epithelium. The aim was to gain more insight in the process of metaplasia and to identify which genes are specifically expressed by the epithelial cells and the surrounding tissues in BE. Hereto, the gene expression profile of a BE epithelial primary cell culture was compared to that of a BE biopsy. To specifically obtain the epithelial cell layer, epithelial cells from biopsies of BE were cultured using a Barrett specific culturing medium. Serial analysis of gene expression was applied to obtain a transcription library of the primary epithelial cell culture. The transcriptome was analyzed and compared to a previously described transcriptome of a BE biopsy. Validation of results by reverse transcriptase-polymerase chain reaction was performed using tissues of 16 BE patients and 16 primary cell cultures. Over 43,000 tags were sequenced. Genes specifically expressed by the Barrett epithelial cells were for instance Lipocalin 2 and Cyclin D1, whereas annexin A10, trefoil factor (TFF)1 and TFF2 were specifically expressed in the BE biopsies. The comparison of the gene expression profiles of BE primary cultured epithelial cells with BE biopsy defines a subset of genes that are specifically expressed by the epithelial cells and another subset that most likely is expressed by the underlying stromal tissues in the BE biopsy specimens.
Subject(s)
Barrett Esophagus/genetics , Barrett Esophagus/pathology , Neoplasm Proteins/genetics , Adult , Aged , Aged, 80 and over , Biopsy , Epithelial Cells/physiology , Female , Gene Expression Profiling , Humans , Male , Middle Aged , Neoplasm Proteins/metabolism , RNA, Messenger/metabolism , Stromal Cells/physiology , Trefoil Factor-2 , Tumor Cells, CulturedABSTRACT
Clinical trials have shown life-prolonging effects of antithrombotics in cancer patients, but the molecular mechanisms remain unknown due to the multitude of their effects. We investigated in a mouse model whether one of the targets of antithrombotic therapy, fibrin deposition, stimulates tumour development. Fibrin may provide either protection of cancer cells in the circulation against mechanical stress and the immune system, or form a matrix for tumours and/or angiogenesis in tumours to develop. Mice homozygous for Factor V Leiden (FVL), a mutation in one of the coagulation factors that facilitates fibrin formation, were used to investigate whether hypercoagulability affects tumour development in an experimental metastasis model. Liver metastases of colon cancer were induced in mice with the FVL mutation and wild-type littermates. At day 21, number and size of tumours at the liver surface, fibrin/fibrinogen distribution, vessel density and the presence of newly formed vessels in tumours were analysed. Number and size of tumours did not differ between mice with and without the FVL mutation. Fibrin/fibrinogen was found in the cytoplasm of hepatocytes and cancer cells, in blood vessels in liver and tumour tissue and diffusely distributed outside vessels in tumours, indicating leaky vessels. Vessel density and angiogenesis varied widely between tumours, but a pre-dominance for vessel-rich or vessel-poor tumours or vessel formation could not be found in either genotype. In conclusion, the FVL mutation has no effect on the development of secondary tumours of colon cancer in livers of mice. Fibrin deposition and thus inhibition of fibrin formation by anticoagulants do not seem to affect tumour development in this model.
Subject(s)
Colonic Neoplasms/pathology , Factor V/genetics , Liver Neoplasms/secondary , Mutation/genetics , Thrombophilia/complications , Animals , Colonic Neoplasms/blood supply , Cytoplasm/pathology , Endothelial Cells/pathology , Fibrin/metabolism , Fibrinogen/metabolism , Homozygote , Liver Neoplasms/blood supply , Liver Neoplasms/pathology , Mice , Mice, Inbred C57BL , Neoplasm Metastasis , Protein Transport , Tumor BurdenABSTRACT
BACKGROUND AND PURPOSE: Intravenous administration of recombinant human activated protein C (rhAPC) is known to reduce lipopolysaccharide (LPS)-induced pulmonary inflammation by attenuating neutrophil chemotaxis towards the alveolar compartment. Ideally, one would administer rhAPC in pulmonary inflammation at the site of infection to minimize the risk of systemic bleeding complications. In this study, we therefore assessed the effect of inhaled rhAPC in a murine model of acute lung injury. EXPERIMENTAL APPROACH: Mice were exposed to LPS (0.5 mg kg(-1): intranasally) to induce acute lung injury. 30 minutes before and 3 hours after LPS exposure mice were subjected to vehicle or rhAPC inhalation (25 or 100 microg per mouse in each nebulization). In order to establish whether rhAPC inhalation affects neutrophil recruitment, neutrophil migration was determined in vitro using a trans-well migration assay. KEY RESULTS: rhAPC inhalation dose-dependently decreased LPS-induced coagulation and inflammation markers in bronchoalveolar lavage fluid (BALF), reduced protein leakage into the alveolar space and improved lung function. In contrast, rhAPC did not prevent LPS-induced neutrophil recruitment into the alveolar space. Neutrophil migration in vitro towards FCS or interleukin (IL)-8 was significantly inhibited by pretreatment with rhAPC (0.01-10 microg ml(-1)], whereas rhAPC (10 microg ml(-1)) added to the chemoattractant (modelling for topical rhAPC administration) did not affect neutrophil migration towards FCS or IL-8. CONCLUSIONS AND IMPLICATIONS: rhAPC inhalation significantly diminished LPS-induced pulmonary inflammation. The benefit of inhaled rhAPC appeared not to involve attenuation of neutrophil recruitment, in contrast to its effects after intravenous administration.